MSLN has been the focus of immunotherapy research since its discovery as a promising therapeutic target for reducing risk of ‘on-target/off-tumor’ toxicities due to its expression profile in normal and cancer tissue [82,83]. The gene discussed is MSLN; the disease is neoplasm.